ArticleInternational journal of environmental research and public health2020
Increasing Incidence of Liposarcoma: A Population-Based Study of National Surveillance Databases, 2001-2016.
Article in International journal of environmental research and public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.Future oncology (London, England) · 2021Trial
- Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial.JAMA oncology · 2021Trial
- Two-stage surgical resection of a massive primary posterior mediastinal dedifferentiated liposarcoma with bilateral thoracic extension: a case report.Annals of medicine and surgery (2012) · 2026Article
- Systemic Options for Recurrent Abdominal Low-grade Well-differentiated Liposarcoma.Current treatment options in oncology · 2026Review
- PPARG governs adipogenic differentiation and cell state plasticity in well-differentiated and dedifferentiated liposarcoma.Science advances · 2026Article
- Pooled Analysis of Trabectedin Efficacy in Myxoid/Round Cell Liposarcoma from Three Prospective Clinical Trials.Cancers · 2026Article
- Liposarcoma: State of the Art-A Scoping Review.Medical sciences (Basel, Switzerland) · 2026Article
- Article
- Article
- Burden and unmet needs of liposarcoma in the United States: Patient perspectives on the liposarcoma diagnostic journey.Rare tumors · 2026Article
- Evaluating shear wave elastography for differentiating lipomas from low to intermediate grade liposarcomas: is it reproducible and reliable?Skeletal radiology · 2025Article
- Recurrent giant retroperitoneal dedifferentiated liposarcoma requiring challenging multiorgan resection: a case report.Journal of medical case reports · 2025Article
- Article
- Article
- Epidemiology, Treatment Patterns, Survival, Healthcare Resource Utilization, and Costs of Dedifferentiated Liposarcoma (DDLPS) in Canada: A Retrospective Cohort Study Using Administrative Databases in Ontario.Current oncology (Toronto, Ont.) · 2025Article
- A rare case of abdominal (lesser sac) myxoid liposarcoma: A case report.International journal of surgery case reports · 2025Article
- Clinical course and prognostic factors of patients with dedifferentiated liposarcoma: a retrospective analysis.BMC cancer · 2025Article
- Chemokine Expression in Well-Differentiated Liposarcoma May Be Involved in the Tumorigenesis of Lymphoplasmacytic Lymphoma: A Case Study.Cancer reports (Hoboken, N.J.) · 2025Article
- Surgical resection of a giant retroperitoneal dedifferentiated liposarcoma: a case report.Frontiers in surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Rare cancers, affecting 1 in 5 cancer patients, disproportionally contribute to cancer mortality. This research focuses on liposarcoma, an understudied rare cancer with unknown risk factors and limited treatment options. Liposarcoma incident cases were identified from the U.S. Surveillance, Epidemiology, and End Result (SEER) program and the combined SEER-National Program of Cancer Registries (CNPCR) between 2001-2016. Incidence rates (age-adjusted and age-specific), 5-year survival, and the time trends were determined using SEER*stat software. Three-dimensional visualization of age-time curves was conducted for males and females. SEER liposarcoma cases represented ~30% (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.